Pharming Group (XAMS:PHARM) Receivables Turnover : 1.75 (As of Mar. 2025)

View and export this data going back to 1998. Start your Free Trial

What is Pharming Group Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Pharming Group's Revenue for the three months ended in Mar. 2025 was €73.2 Mil. Pharming Group's average Accounts Receivable for the three months ended in Mar. 2025 was €41.8 Mil. Hence, Pharming Group's Receivables Turnover for the three months ended in Mar. 2025 was 1.75.

Pharming Group Receivables Turnover Historical Data

The historical data trend for Pharming Group's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Receivables Turnover Chart

Pharming Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Receivables Turnover

Get a 7-Day Free Trial

7.70

9.96

10.85

8.61

7.87

Pharming Group Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Receivables Turnover	Get a 7-Day Free Trial															1.50	1.66	1.48	2.13	1.75

Competitive Comparison of Pharming Group's Receivables Turnover

For the Biotechnology subindustry, Pharming Group's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharming Group's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Pharming Group's Receivables Turnover falls into.

Save Embed

;

Save Embed

;

Pharming Group Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Pharming Group's Receivables Turnover for the fiscal year that ended in Dec. 2024 is calculated as

	Receivables Turnover (A: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2024 )	/ (	(Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )
=	283.826	/ (	(32.469	+	39.662)	/	2 )
=	283.826	/	36.0655
=	7.87

Pharming Group's Receivables Turnover for the quarter that ended in Mar. 2025 is calculated as

	Receivables Turnover (Q: Mar. 2025 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2025 )	/ (	(Accounts Receivable (Q: Dec. 2024 )	+	Accounts Receivable (Q: Mar. 2025 ))	/	count )
=	73.162	/ (	(39.662	+	43.925)	/	2 )
=	73.162	/	41.7935
=	1.75

Pharming Group (XAMS:PHARM) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Pharming Group Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Pharming Group's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (XAMS:PHARM) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

PHAR:USA PHGUF:USA 0QCO:UK PHG:Germany PHGN:Germany

Address

Darwinweg 24, Leiden, ZH, NLD, 2333 CR

Website

https://www.pharming.com

Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.

Pharming Group Headlines

No Headlines